A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)

NCT00531232 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes
Secondary Acute Myeloid Leukemia (AML)

Interventions

DRUG: Clofarabine

Sponsor

Genzyme, a Sanofi Company